Restoring Lost Synapses in ALS, Fragile X and More with Spinogenix’s Dr. Peter Vanderklish — Episode 233
SPG601 calms brain activity in men with fragile X, helping them to focus
Spinogenix Receives Positive FDA Feedback for SPG601 in Fragile X Syndrome
SPG601 granted orphan drug status in EU for treating fragile X
SPG601 found to reduce measure of abnormal brain activity in fragile X
FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of FXS
FDA Designation for SPG601 Highlights New Hope for FXS Treatment
Novel BK Channel Activator Fast Tracked for Fragile X Syndrome
Personalized medicine; astroglia organoids; fast track for fragile X drug
Spinogenix’s SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome
